+

Please type a plus sign (+) inside this box →

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OIPE		Application Number	10/561,583			
To a solution of the solution	•	Filing Date	March 15, 2007			
AUG 2 9 2007 TRANSMITTAL FORM		First Named Inventor	VAN WAMEL, WILLEM JAN BASTIAAN Not yet assigned			
		Group Art Unit				
that the oe used for all correspondence after initial	be used for all correspondence after initial filing)		Not yet assigned			
Total Number of Pages in This Submissi	on 3	Attorney Docket Number	ARSI-012			
ENCLOSURES (check all that apply)						
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement SB08A Form (total 2 pgs.) Certified Copy of Priority Documents Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Control Cont	ing-related Papers n to Convert to a onal Application of Attorney, Revocation e of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): References Return Postcard			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Signing Attorney/Agent (Reg. No.) CAROLL. FRANCIS, PH.D., 36,513 BOZICEVIC, FIELD & FRANCIS, LAPA						
Signature (dub)	mu.					
Date August 29, 2007						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL LABEL NO. EV 955 153 725 US

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 955 153 725 US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	ARSI-012	
First Named Inventor	VAN WAMEL, WILLEM JAN	
Application Number	10/561,583	
Confirmation No.	6152	
Filing Date	March 15, 2007	
Group Art Unit	Not yet assigned	
Examiner Name	Not yet assigned	
	· · · · · · · · · · · · · · · · · · ·	

Title: "THERAPEUTIC USE OF LPI, A

STAPHYLOCOCCAL LECTIN PATHWAY INHIBITOR IN INFLAMMATORY DISEASES"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. ARSI-012 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

By:

Carol L. Francis, Ph.D

Registration No. 36,513

Date: 1729

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

PTO/SB/08a (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Reduction Act of 19 Under the Paperwo

Substitute for form

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/561,583 Filing Date March 15, 2007 VAN WAMEL, WILLEM JAN BASTIAAN First Named Inventor Art Unit Not yet assigned Examiner Name Not yet assigned ARSI-012

(Use as many sheets as necessary) Sheet

U.S. PATENT DOCUMENTS Examiner Cite **Document Number Publication Date** Name of Patentee or Pages, Columns, Lines, Where Initials' No.1 MM-DD-YYYY Relevant Passages or Relevant Applicant of Cited Document Number-Kind Code² (if known) Figures Appear US-US-

Attorney Docket Number

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document			Pages, Columns, Lines,	
Examiner Initials'	Cite No. ¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
					·	

Exam				
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
)./	DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Hypothetical protein SA1754." Retrieved from EBI accession no. UNITPROT:Q99SU9 Database accession no. Q99SU9_STAAN;			
./	DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Fibrinogen binding protein." Retrieved from EBI accession no. UNITPROT:Q99UU9 Database accession no. Q99UU9_STAAN.			
	·			
	No. ¹	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Hypothetical protein SA1754." Retrieved from EBI accession no. UNITPROT:Q99SU9 Database accession no. Q99SU9_STAAN; DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Fibrinogen binding protein." Retrieved from EBI accession no. LINITPROT:Q99UIJI9 Database accession no. Q99UIJI9 STAAN		

Examiner		Date	00/00/0040
Signature	/Patricia Duffy/	Considered	06/08/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.